[1]De Luca D, Tingay DG, van Kaam AH, et al. Epidemiology of neonatal acute respiratory distress syndrome: prospective, multicenter, international cohort study[J]. Pediatr Crit Care Med, 2022, 23:524-534. [2]Hong H, Fu B, Wang R. Clinical value of serum miR-92 and miR-122 expression level combined with pulmonary ultrasound score in the prognosis of neonatal acute respiratory distress syndrome[J]. J Clin Lab Anal, 2022, 36:e24485-e24496.doi:10.1002/jcla.24485. [3]Nucera F, Lo BF, Shen SS, et al. Role of atypical chemokines and chemokine receptors pathways in the pathogenesis of COPD[J]. Curr Med Chem, 2021, 28:2577-2653. [4]Christopoulou ME, Aletras AJ, Papakonstantinou E, et al. WISP1 and macrophage migration inhibitory factor in respiratory inflammation: novel insights and therapeutic potentials for asthma and COPD[J]. Int J Mol Sci, 2024, 25:10049-10080. [5]宋婷阁, 张鹏举, 耿彪, 等. 新生儿急性呼吸窘迫综合征患者血清miR-183-5p的表达及与IL-1β,IL-6和TNF-α水平的相关性[J]. 现代检验医学杂志,2021,36:55-68. [6]匡凤梧, 许峰. 新生儿呼吸窘迫综合征的诊断和治疗[J]. 中国实用妇科与产科杂志, 2003, 19:335-337. [7]Sweet DG, Carnielli VP, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome: 2022 Update[J]. Neonatology, 2023, 120:3-23. [8]张雨茜, 王荣花, 陈祥, 等. TLR4信号通路介导病毒性急性肺损伤与ARDS的研究进展[J]. 病毒学报, 2021, 37:1234-1243. [9]Jalce G, Guignabert C. Multiple roles of macrophage migration inhibitory factor in pulmonary hypertension[J]. Am J Physiol Lung Cell Mol Physiol, 2020, 318:L1-L9. [10]Bayraktar S, Tanyeri BB, Kihliç Ü. Umbilical cord levels of macrophage migration inhibitory factor in neonatal respiratory distress syndrome[J]. Turk J Med Sci, 2021, 51:722-726. [11]Li X, Liu H. Expression and prognostic value of MIP-1α in neonatal acute respiratory distress syndrome[J]. Am J Transl Res, 2022, 14:7889-7897. [12]Rong W, Liu C, Li X, et al. Caspase-8 promotes pulmonary hypertension by activating macrophage-associated inflammation and IL-1β (Interleukin 1β) production[J]. Arterioscler Thromb Vasc Biol, 2022, 42:613-631.
|